Lifebank Cryogenics Corp.

Lifebank Cryogenics Corp.

June 22, 2005 07:00 ET

Lifebank Appoints Preeminent Hematologist to Advisory Board

BURNABY, BRITISH COLUMBIA--(CCNMatthews - June 22, 2005) - Lifebank Cryogenics Corp. (TSX VENTURE:LBK) is pleased to announce that Dr. Pierre Laneuville, BSc, M.D., FRCP(C), has agreed to join its medical and scientific advisory board.

Dr. Laneuville is a senior physician in the division of hematology, department of medicine at Montreal's Royal Victoria Hospital, and an associate professor in the department of medicine at McGill University. He is also the current vice-president and the next president of the Canadian Hematology Association.

Dr. Laneuville graduated in 1978 with honours in biochemistry from McMaster University and received his M.D. from the University of Ottawa in 1982. He completed his clinical training at Royal Victoria Hospital, McGill University, in internal medicine in 1985 and in hematology in 1987. Since then, he has held numerous posts at both the Royal Victoria Hospital and McGill University.

Dr. Laneuville's research interests are in the molecular biology of chronic myelogenous leukemia, genomic instability in cancer, in addition to hematopoietic stem cell transplantation. He has authored or co-authored over 75 published manuscripts and abstracts related to his research and lectures extensively across Canada and internationally. In 2002, at Montreal's Royal Victoria Hospital, Dr. Laneuville led the first surgery to successfully transplant umbilical cord blood cells collected from a child to replenish the bone marrow of the mother suffering from leukemia.

"We are pleased that Dr. Laneuville has agreed to offer his insight and expertise on our advisory board," states Ernest Stacey, President of Lifebank. "He is a leading authority on the causes and treatment of blood disorders and his contribution will help ensure Lifebank remains at the forefront of stem cell science and bring national recognition to stem cell banking services."

The appointment of Dr. Laneuville follows the recent announcement of an exclusive licensing agreement for a new technology developed by the University of Alberta that has the potential to set a new clinical standard for stem cell storage and preservation. The technology, once commercialized, is expected to enhance the number of functional cells available for transplant to treat a variety of blood disorders and cancers.

Commenting on his appointment to Lifebank's medical and scientific advisory board, Dr. Laneuville said; "There is a natural fit between my research interests and Lifebank's work to commercialize technology that is at the forefront of stem cell storage. I am looking forward to working in collaboration with Lifebank and it's existing team of medical and scientific experts."

Lifebank is a biomedical service company that provides processing and cryogenic (ultra low temperature) storage of umbilical cord blood stem cells. It is the first AABB accredited umbilical cord blood stem cell bank in Canada. Lifebank has successfully stored stem cell samples for clients in Canada and the rest of the world. Lifebank is dedicated to providing its clients with the finest cord blood stem cell processing, analysis and cryogenic storage services available in the world. Lifebank strives to work closely with physicians and public institutions in order to provide life saving cord blood services to any and all persons in need.

A full press release on Lifebank's exclusive technology licensing agreement with the University of Alberta is available at

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information